Opinion

Video

Adverse Effect Management and the Role of Immunotherapy in NMIBC

Author(s):

Gordon A. Brown, DO,Siamak Daneshmand, MD

Experts on bladder cancer discusses strategies to minimize adverse effects and the role of immunotherapy in BCG-unresponsive NMIBC treatment paradigms.

Current Time 0:00
Duration 4:48
Loaded: 3.40%
Stream Type LIVE
Remaining Time 4:48
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected
    Related Videos
    4 experts in this video
    Non–Muscle Invasive-Bladder Cancer Overview
    Laura Davis, MD, on link between microplastics and bladder cancer
    Laura Davis, MD, on link between microplastics and bladder cancer
    Rebecca A. Campbell, MD, answers a question during a Zoom video interview
    Rebecca A. Campbell, MD, discusses citation rates for men and women in the oncology literature
    Sam Chang, MD, shares updated data on nogapendekin alfa inbakicept in NMIBC
    Sam Chang, MD, shares updated data on nogapendekin alfa inbakicept in NMIBC
    Joshua J. Meeks, MD, PhD, gives an answer during a Zoom video interview
    Expert discusses the NMIBC trials landscape
    John Gore, MD, on bladder preservation in muscle–invasive bladder cancer
    John Gore, MD, on bladder preservation in muscle–invasive bladder cancer
    Félix Guerrero-Ramos, MD, on TAR-200 in papillary disease-only NMIBC
    Félix Guerrero-Ramos, MD, on TAR-200 in papillary disease-only NMIBC
    Joshua J. Meeks, MD, PhD, answers a question during a Zoom video interview
    Joshua J. Meeks, MD, PhD, discusses NIAGARA data for patient undergoing cystectomy
    Joseph Jacob, MD, on the durability of TAR-200 in NMIBC
    Joseph Jacob, MD, on the durability of TAR-200 in NMIBC
    Study data point to gender disparities in oncology research citations
    Study data point to gender disparities in oncology research citations
    Related Content
    Urologic surgeons successfully complete world’s first bladder transplant
    May 19th 2025

    Urologic surgeons successfully complete world’s first bladder transplant

    Hannah Clarke
    The bladder transplant procedure involved a collaboration between the University of California, Los Angeles and the University of Southern California.
    medical depiction of bladder cancer
    May 31st 2023

    Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

    Urology Times staff
    In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.
    Disitamab vedotin plus toripalimab extends PFS, OS in HER2-positive la/mUC
    May 12th 2025

    Disitamab vedotin plus toripalimab extends PFS, OS in HER2-positive la/mUC

    Hannah Clarke
    The phase 3 RC48-C016 trial met its primary end points.
    Dr. Lutz on sexual dysfunction, performance anxiety, and Peyronie's disease
    May 26th 2022

    Dr. Lutz on sexual dysfunction, performance anxiety, and Peyronie's disease

    Urology Times staff
    “We know that erectile dysfunction is really an important issue that can be a harbinger for other underlying cardiovascular or neurological health issues,” says Michael Lutz, MD.
    Physical function and frailty measures offer distinct insights in patients with bladder cancer
    May 7th 2025

    Physical function and frailty measures offer distinct insights in patients with bladder cancer

    Hannah Clarke
    Data showed that physical function and self-reported frailty assessments were poorly correlated.
    FDA to host advisory committee meeting on UGN-102 for NMIBC
    May 7th 2025

    FDA to host advisory committee meeting on UGN-102 for NMIBC

    Hannah Clarke
    The Oncologic Drugs Advisory Committee meeting is scheduled for May 21, 2025.
    © 2025 MJH Life Sciences

    All rights reserved.